Warning: Trying to access array offset on value of type bool in /mnt/BLOCKSTORAGE/home/1018056.cloudwaysapps.com/ucfwgyvtrf/public_html/wp-content/plugins/wp-word-count/public/class-wpwc-public.php on line 123
A new scientific breakthrough has been made in the field of Alzheimer’s research – a drug called donanemab that could be a game-changer for some patients. This drug is specifically designed to target proteins in the brain, which could slow down memory impairment and provide relief to those affected by this devastating disease.
1. Donanemab is a new Alzheimer’s drug that has been found to slow the progression of the disease.
2. In the trials, donanemab appears to have slowed the pace of the disease by about a third.
3. It is awaiting approval from a regulator.
If donanemab is given to an Alzheimer’s patient early on in the disease, it is said to have the best results. This is because donanemab works by targeting and clearing protein pieces called amyloid plaques in the brain, which can contribute to inflammation and damage to brain cells, leading to cognitive decline.
The trial of the drug shows that its efficacy continues even after treatment has stopped, so the patient can benefit for some time even without the drug while still showing signs of improvements in their condition. Tests have shown that donanemab can slow the progression of memory and thinking problems by about a third in certain cases, and even more if the patient is mildly impaired.
Alzheimer’s disease is characterized by memory loss, mood changes and disorders, increased confusion, withdrawal from social activities, and difficulty with language and reading. Unfortunately, it progresses from a mild illness to a severe one in most cases, and can eventually lead to the patient being unable to communicate or even control his or her bodily functions.
Donanemab is currently awaiting approval from a regulator, so until then, it is not available for use. The US FDA is expected to decide whether to approve the drug by the end of this year, and submissions to other global regulatory bodies are underway as well.
The drug does have some side effects, mainly brain bleeding and in a few cases, death, but doctors will likely be able to monitor these risks with magnetic resonance imaging (MRI) and stop the drug if necessary.
It is clear that a major step forward has been made in the fight against Alzheimer’s disease and the hope is that the new drug, donanemab, will be approved and be available soon to help improve the lives of those affected by this disease